EC
BBNX

EntryPoint Capital’s Beta Bionics BBNX Stock Holding History

EntryPoint Capital’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Buy
+27,372
New +$326K 0.1% 385

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

EntryPoint Capital's BBNX Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Beta Bionics (BBNX) in Q2 2026: 27,372 shares worth $429K. The stake represents 0.1% of the portfolio and ranks #385 among its holdings.

134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • EntryPoint Capital held 27,372 shares of Beta Bionics worth $429K as of Q2 2026.
  • Beta Bionics was a new EntryPoint Capital position in Q2 2026.
  • Beta Bionics made up 0.1% of EntryPoint Capital's portfolio in Q2 2026, its #385 holding.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.